Please find attached the First Quarter Report 2026 for SoftOx Solutions AS.
Click here for more information
© Oslo Bors ASA, source Oslo Stock Exchange
SoftOx Solutions AS: First Quarter Report 2026
Earlier from SoftOx Solutions AS
- SoftOx Solutions AS: SoftOx Solutions AS exercises on the financing facility with Long State Investments Limited
- SoftOx Solutions AS: SIS-03 DOSE-ESCALATION PHASE COMPLETED AND INITIATION OF PROOF-OF-CONCEPT PHASE
- SoftOx Solutions AS: FIRST PARTICIPANT ENROLLED IN BIODEFENCE-FOCUSED SIS-02 PHASE 1 CLINICAL STUDY
- SoftOx Solutions AS: Annual Report 2025
- SoftOx Solutions AS: New Share Capital
Later from SoftOx Solutions AS
- SoftOx Solutions AS: POSITIVE TOPLINE SAFETY DATA FROM SIS-03 DOSE-ESCALATION PHASE
- SoftOx Solutions AS: FIRST PATIENT DOSED IN SIS-03 PROOF-OF-CONCEPT PATIENT TRIAL
- SoftOx Solutions AS: Half Year Report 2026
- SoftOx Solutions AS: SoftOx attracts renowned inhaled antimicrobial expert Dr. Bruce Montgomery to lead Clinical Advisory Board ahead of Phase 2b
Follow SoftOx Solutions AS into a list and get an email when it puts out news.
Follow SoftOx Solutions AS